ASCO 2019: The Courage and Expertese to Outsmarting Cancer

In this episode of The Onco’Zine Brief Peter Hofland report from the annual meeting of the American Society of Clinical Oncology – ASCO – which was held May 31st – June 4th, 2019. The American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. During the annual meeting Peter Hofland spoke with: •Anna Protopapas, the president and Chief Executive Office of Mersana Therapeutics, a clinical stage biotech company developing antibody-drug conjugates – a very specific kind of targeted anti-cancer drug, I also talk with •Eliran Malki, the Chief executive officer of BELONG.life, the world’s largest social network for cancer patients and caregivers designed to gain a better understanding of the cancer patient journey, with the goal of optimizing treatment and outcomes. •Dr. Rod Humerickhouse, asset strategy leader oncology at AbbVie, a highly focused research-driven biopharmaceutical company. As a major developer of anticancer drugs, AbbVie’s oncology scientists understand that outsmarting cancer takes a potent combination of courage, scientific expertise and strategy. For more information, go to Onco'Zine at www.oncozine.com